scholarly article | Q13442814 |
P356 | DOI | 10.1074/JBC.M410480200 |
P698 | PubMed publication ID | 15545269 |
P2093 | author name string | Keith A Hruska | |
Toshifumi Sugatani | |||
P2860 | cites work | TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src | Q28142620 |
NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase | Q28144326 | ||
NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling | Q28144330 | ||
Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene | Q28349476 | ||
Osteoclast differentiation and activation | Q29547556 | ||
Cellular survival: a play in three Akts | Q29547806 | ||
Regulation of neuronal survival by the serine-threonine protein kinase Akt | Q29614185 | ||
PKB/AKT: functional insights from genetic models | Q34389540 | ||
Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts | Q35126799 | ||
Insulin signaling through Akt/protein kinase B analyzed by small interfering RNA-mediated gene silencing | Q35146125 | ||
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies | Q35653049 | ||
Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. | Q35965439 | ||
Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase | Q36103541 | ||
Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation | Q36490362 | ||
Interleukin 3-dependent survival by the Akt protein kinase | Q36593239 | ||
The extracellular matrix as a cell survival factor | Q40241699 | ||
Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. | Q40323778 | ||
PTEN regulates RANKL- and osteopontin-stimulated signal transduction during osteoclast differentiation and cell motility | Q40686068 | ||
NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis | Q44049672 | ||
Activin A stimulates IkappaB-alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors | Q44561312 | ||
M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase | Q44591611 | ||
Positive feedback regulation between Akt2 and MyoD during muscle differentiation. Cloning of Akt2 promoter | Q48309099 | ||
Raf/MAPK and rapamycin-sensitive pathways mediate the anti-apoptotic function of p21Ras in IL-3-dependent hematopoietic cells | Q57895767 | ||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 3583-3589 | |
P577 | publication date | 2004-11-15 | |
P1433 | published in | Journal of Biological Chemistry | Q867727 |
P1476 | title | Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors | |
P478 | volume | 280 |
Q33274330 | A constitutive endogenous osteopontin production is important for macrophage function and differentiation |
Q36106338 | A short report: PAMM, a novel antioxidant protein, induced by oxidative stress |
Q38348926 | AATF mediates an antiapoptotic effect of the unfolded protein response through transcriptional regulation of AKT1 |
Q41284390 | AKT induces senescence in primary esophageal epithelial cells but is permissive for differentiation as revealed in organotypic culture. |
Q33871498 | AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species. |
Q35236076 | Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. |
Q34752434 | Adiponectin inhibits osteoclastogenesis and bone resorption via APPL1-mediated suppression of Akt1. |
Q92960044 | Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma |
Q33303666 | Akt1 in osteoblasts and osteoclasts controls bone remodeling |
Q43223814 | An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption. |
Q42488670 | Autophagy and 3-Phosphoinositide-Dependent Kinase 1 (PDK1)-Related Kinome in Pagetic Osteoclasts |
Q37883974 | Bim: guardian of tissue homeostasis and critical regulator of the immune system, tumorigenesis and bone biology |
Q40323078 | Blocking mammalian target of rapamycin alleviates bone cancer pain and morphine tolerance via µ-opioid receptor |
Q33794615 | Bone Size and Quality Regulation: Concerted Actions of mTOR in Mesenchymal Stromal Cells and Osteoclasts |
Q92415836 | Cathepsin K inhibition-induced mitochondrial ROS enhances sensitivity of cancer cells to anti-cancer drugs through USP27x-mediated Bim protein stabilization |
Q34703754 | Cloning of B cell-specific membrane tetraspanning molecule BTS possessing B cell proliferation-inhibitory function |
Q46973605 | Colony-stimulating factor-1 requires PI3-kinase-mediated metabolism for proliferation and survival in myeloid cells |
Q36968719 | Cross-talk between the Akt and NF-kappaB signaling pathways inhibits MEHP-induced germ cell apoptosis |
Q49989200 | Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines |
Q37361165 | Distinct actions of Akt1 and Akt2 in skeletal muscle differentiation |
Q35129460 | Distinct actions of akt1 on skeletal architecture and function |
Q48495085 | Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death |
Q42409094 | Effects of Src-kinase inhibition in cancer-induced bone pain. |
Q35613027 | Erythropoietin mediated bone formation is regulated by mTOR signaling |
Q36532578 | Future anti-catabolic therapeutic targets in bone disease |
Q37035480 | Fyn promotes proliferation, differentiation, survival and function of osteoclast lineage cells |
Q35531128 | Gab2 promotes colony-stimulating factor 1-regulated macrophage expansion via alternate effectors at different stages of development. |
Q27341203 | Genomic analysis of the function of the transcription factor gata3 during development of the mammalian inner ear |
Q38171327 | Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside |
Q54574990 | Hyperactivation of mTOR critically regulates abnormal osteoclastogenesis in neurofibromatosis Type 1. |
Q34430216 | Hypoxia enhances the proliferative response of macrophages to CSF-1 and their pro-survival response to TNF. |
Q34510163 | Identification of novel type 2 diabetes candidate genes involved in the crosstalk between the mitochondrial and the insulin signaling systems |
Q38753100 | Implications of the Interaction Between miRNAs and Autophagy in Osteoporosis |
Q51308225 | Inactivation of Regulatory-associated Protein of mTOR (Raptor)/Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in Osteoclasts Increases Bone Mass by Inhibiting Osteoclast Differentiation in Mice. |
Q36926972 | Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone |
Q94564497 | Integrative Analysis for Elucidating Transcriptomics Landscapes of Glucocorticoid-Induced Osteoporosis |
Q93109056 | Isoform-Specific Role of Akt in Oral Squamous Cell Carcinoma |
Q48187280 | Mammalian target of rapamycin as a therapeutic target in osteoporosis |
Q39233604 | Mechanistic target of rapamycin small interfering RNA and rapamycin synergistically inhibit tumour growth in a mouse xenograft model of human oesophageal carcinoma |
Q51005199 | Metabolic regulation of osteoclast differentiation and function. |
Q43781342 | Micro-CT imaging analysis for the effect of celecoxib, a cyclooxygenase-2 inhibitor, on inflammatory bone destruction in adjuvant arthritis rats |
Q36532524 | Molecular mechanism of the life and death of the osteoclast |
Q35953074 | Mutation in Osteoactivin Promotes Receptor Activator of NFκB Ligand (RANKL)-mediated Osteoclast Differentiation and Survival but Inhibits Osteoclast Function |
Q61814977 | Ninjurin1 positively regulates osteoclast development by enhancing the survival of prefusion osteoclasts |
Q35252690 | Pathway analysis of microRNA expression profile during murine osteoclastogenesis |
Q40241184 | Quantitative analysis of anti-apoptotic function of Akt in Akt1 and Akt2 double knock-out mouse embryonic fibroblast cells under normal and stressed conditions |
Q42136336 | RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro |
Q38749340 | RLIP76 increases apoptosis through Akt/mTOR signaling pathway in gastric cancer |
Q28482104 | RLIP76 regulates PI3K/Akt signaling and chemo-radiotherapy resistance in pancreatic cancer |
Q58776864 | Rab GTPases in Osteoclastic Endomembrane Systems |
Q45057583 | Rapamycin unbalances the polarization of human macrophages to M1. |
Q36047103 | Regulation of IKKε Expression by Akt2 Isoform |
Q38749702 | Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt |
Q45035896 | Regulation of bone resorption and sealing zone formation in osteoclasts occurs through protein kinase B-mediated microtubule stabilization |
Q34110611 | Regulation of pancreatic duct cell differentiation by phosphatidylinositol-3 kinase. |
Q37635761 | RelB-induced expression of Cot, an MAP3K family member, rescues RANKL-induced osteoclastogenesis in alymphoplasia mice by promoting NF-κB2 processing by IKKα. |
Q37358983 | Rheumatoid factor positivity is associated with increased joint destruction and upregulation of matrix metalloproteinase 9 and cathepsin k gene expression in the peripheral blood in rheumatoid arthritic patients treated with methotrexate |
Q35310728 | Role of extracellular matrix renal tubulo-interstitial nephritis antigen (TINag) in cell survival utilizing integrin (alpha)vbeta3/focal adhesion kinase (FAK)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B-serine/threonine kinase (AKT) signal |
Q89613496 | Rutin promotes osteogenic differentiation of periodontal ligament stem cells through the GPR30-mediated PI3K/AKT/mTOR signaling pathway |
Q35665655 | Selective signaling by Akt1 controls osteoblast differentiation and osteoblast-mediated osteoclast development |
Q33627269 | Selective signaling by Akt2 promotes bone morphogenetic protein 2-mediated osteoblast differentiation |
Q34182834 | Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data |
Q33851600 | TGF-β inducible early gene 1 regulates osteoclast differentiation and survival by mediating the NFATc1, AKT, and MEK/ERK signaling pathways |
Q54597646 | TNFα-mediated apoptosis in human osteoarthritic chondrocytes sensitized by PI3K-NF-κB inhibitor, not mTOR inhibitor. |
Q48527868 | TSC1 regulates osteoclast podosome organization and bone resorption through mTORC1 and Rac1/Cdc42. |
Q37152195 | Targeted overexpression of BSP in osteoclasts promotes bone metastasis of breast cancer cells |
Q38733725 | The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts. |
Q53338072 | The PI3K/AKT cell signaling pathway is involved in regulation of osteoporosis. |
Q92881718 | The Roles of FoxO Transcription Factors in Regulation of Bone Cells Function |
Q38960721 | The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. |
Q40291978 | The role of the nuclear Akt activation and Akt inhibitors in all-trans-retinoic acid-differentiated HL-60 cells |
Q37185295 | Trolox prevents osteoclastogenesis by suppressing RANKL expression and signaling |
Q35149607 | Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion |
Q35126991 | Unraveling the role of FoxOs in bone--insights from mouse models |
Q33588700 | Validation of anti-aging drugs by treating age-related diseases |
Q36324934 | alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology |
Q64095786 | mTOR inhibitor and bone-targeted drugs break the vicious cycle between clear-cell renal carcinoma and osteoclasts in an in vitro co-culture model |
Q52646519 | mTORC1 Inhibits NF-κB/NFATc1 Signaling and Prevents Osteoclast Precursor Differentiation, In Vitro and In Mice. |
Search more.